Factors predicting resolution of left ventricular thrombus in different time windows after myocardial infarction.
Humans
Male
Female
Middle Aged
Time Factors
Thrombosis
/ diagnostic imaging
Aged
Risk Factors
Anticoagulants
/ therapeutic use
C-Reactive Protein
/ analysis
Retrospective Studies
Myocardial Infarction
/ diagnostic imaging
Biomarkers
/ blood
Treatment Outcome
Heart Diseases
/ diagnostic imaging
Heart Ventricles
/ diagnostic imaging
China
Echocardiography
Ventricular Function, Left
Cardiovascular system
Embolism
Left ventricular
Myocardial infarction
Thrombosis
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
29 May 2024
29 May 2024
Historique:
received:
12
11
2023
accepted:
23
04
2024
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
29
5
2024
Statut:
epublish
Résumé
Left ventricular thrombus (LVT) is a serious complication after myocardial infarction. However, due to its asymptomatic nature, early detection is challenging. We aimed to explore the differences in clinical correlates of LVT found in acute to subacute and chronic phases of myocardial infarction. We collected data from 153 patients who were diagnosed with LVT after myocardial infarction at the Affiliated Hospital of Qingdao University from January 2013 to December 2022. Baseline information, inflammatory markers, transthoracic echocardiograph (TTE) data and other clinical correlates were collected. Patients were categorized into acute to subacute phase group (< 30 days) and chronic phase group (30 days and after) according to the time at which echocardiograph was performed. The resolution of thrombus within 90 days is regarded as the primary endpoint event. We fitted logistic regression models to relating clinical correlates with phase-specific thrombus resolution. For acute to subacute phase thrombus patients: C-reactive protein levels (OR: 0.95, 95% CI: 0.918-0.983, p = 0.003) were significantly associated with thrombus resolution. For chronic phase thrombus patients: anticoagulant treatment was associated with 5.717-fold odds of thrombus resolution (OR: 5.717, 95% CI: 1.543-21.18, p = 0.009). Higher levels of CRP were associated with lower likelihood of LVT resolution in acute phase myocardial infarction; Anticoagulant therapy is still needed for thrombus in the chronic stage of myocardial infarction.
Sections du résumé
BACKGROUND
BACKGROUND
Left ventricular thrombus (LVT) is a serious complication after myocardial infarction. However, due to its asymptomatic nature, early detection is challenging. We aimed to explore the differences in clinical correlates of LVT found in acute to subacute and chronic phases of myocardial infarction.
METHODS
METHODS
We collected data from 153 patients who were diagnosed with LVT after myocardial infarction at the Affiliated Hospital of Qingdao University from January 2013 to December 2022. Baseline information, inflammatory markers, transthoracic echocardiograph (TTE) data and other clinical correlates were collected. Patients were categorized into acute to subacute phase group (< 30 days) and chronic phase group (30 days and after) according to the time at which echocardiograph was performed. The resolution of thrombus within 90 days is regarded as the primary endpoint event. We fitted logistic regression models to relating clinical correlates with phase-specific thrombus resolution.
RESULTS
RESULTS
For acute to subacute phase thrombus patients: C-reactive protein levels (OR: 0.95, 95% CI: 0.918-0.983, p = 0.003) were significantly associated with thrombus resolution. For chronic phase thrombus patients: anticoagulant treatment was associated with 5.717-fold odds of thrombus resolution (OR: 5.717, 95% CI: 1.543-21.18, p = 0.009).
CONCLUSIONS
CONCLUSIONS
Higher levels of CRP were associated with lower likelihood of LVT resolution in acute phase myocardial infarction; Anticoagulant therapy is still needed for thrombus in the chronic stage of myocardial infarction.
Identifiants
pubmed: 38811882
doi: 10.1186/s12872-024-03898-9
pii: 10.1186/s12872-024-03898-9
doi:
Substances chimiques
Anticoagulants
0
C-Reactive Protein
9007-41-4
Biomarkers
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
278Subventions
Organisme : the Shandong Provincial Natural Science Foundation
ID : ZR2023MH337
Informations de copyright
© 2024. The Author(s).
Références
Nihoyannopoulos P, Smith GC, Maseri A, Foale RA. The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity. J Am Coll Cardiol. 1989;14(4):903–11.
doi: 10.1016/0735-1097(89)90463-4
pubmed: 2794276
Gianstefani S, Douiri A, Delithanasis I, Rogers T, Sen A, Kalra S, Charangwa L, Reiken J, Monaghan M, MacCarthy P. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol. 2014;113(7):1111–6.
doi: 10.1016/j.amjcard.2013.12.015
pubmed: 24485697
Stein B, Fuster V. Antithrombotic therapy in acute myocardial infarction: prevention of venous, left ventricular and coronary artery thromboembolism. Am J Cardiol. 1989;64(4):b33–40.
doi: 10.1016/S0002-9149(89)80008-6
McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi JL Jr., Bhatt DL, McEvoy JW. Left ventricular Thrombus after Acute myocardial infarction: screening, Prevention, and treatment. JAMA Cardiol. 2018;3(7):642–9.
doi: 10.1001/jamacardio.2018.1086
pubmed: 29800958
Gökdeniz T, Boyacı F, Hatem E, Aslan AO, Aykan A, Gül I, Turan T, Kalaycıoğlu E, Celik Ş. SYNTAX score predicts the left ventricle thrombus development in patients undergoing primary percutaneous coronary intervention for first anterior myocardial infarction. Clin Appl Thromb Hemost. 2014;20(7):698–705.
doi: 10.1177/1076029613478158
pubmed: 23434922
Jiang YX, Jing LD, Jia YH. Clinical characteristics and risk factors of left ventricular Thrombus after Acute myocardial infarction: a matched case-control study. Chin Med J (Engl). 2015;128(18):2415–9.
doi: 10.4103/0366-6999.164869
pubmed: 26365955
Lechner I, Reindl M, Tiller C, Holzknecht M, Fink P, Plangger J, Mayr A, Klug G, Bauer A, Reinstadler SJ, Metzler B. Association between inflammation and left ventricular thrombus formation following ST-elevation myocardial infarction. Int J Cardiol. 2022;361:1–6.
doi: 10.1016/j.ijcard.2022.05.009
pubmed: 35533756
Meurin P, Brandao Carreira V, Dumaine R, Shqueir A, Milleron O, Safar B, Perna S, Smadja C, Genest M, Garot J, Carette B, Payot L, Tabet JY. Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: a prospective multicenter study. Am Heart J. 2015;170(2):256–62.
doi: 10.1016/j.ahj.2015.04.029
pubmed: 26299222
Gellen B, Biere L, Logeart D, Lairez O, Vicaut E, Furber A, Mercadier JJ, Sirol M. Timing of Cardiac magnetic resonance imaging impacts on the detection rate of Left ventricular Thrombus after myocardial infarction. JACC Cardiovasc Imaging. 2017;10(11):1404–5.
doi: 10.1016/j.jcmg.2016.12.006
pubmed: 28216006
Yang Q, Lang X, Quan X, Gong Z, Liang Y. Different Oral Antithrombotic Therapy for the Treatment of Ventricular Thrombus: An Observational Study from 2010 to 2019. Int J Clin Pract 2022, 2022, 7400860.
Bass ME, Kiser TH, Page RL 2nd;, McIlvennan CK, Allen LA, Wright G, Shakowski C. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021;52(2):517–22.
Robinson AA, Trankle CR, Eubanks G, Schumann C, Thompson P, Wallace RL, Gottiparthi S, Ruth B, Kramer CM, Salerno M, Bilchick KC, Deen C, Kontos MC, Dent J. Off-label use of direct oral anticoagulants compared with Warfarin for Left Ventricular Thrombi. JAMA Cardiol. 2020;5(6):685–92.
doi: 10.1001/jamacardio.2020.0652
pubmed: 32320043
pmcid: 7177639
Abdelnabi M, Saleh Y, Fareed A, Nossikof A, Wang L, Morsi M, Eshak N, Abdelkarim O, Badran H, Almaghraby A. Comparative study of oral anticoagulation in Left Ventricular Thrombi (No-LVT trial). J Am Coll Cardiol. 2021;77(12):1590–2.
doi: 10.1016/j.jacc.2021.01.049
pubmed: 33766266
Guddeti RR, Anwar M, Walters RW, Apala D, Pajjuru V, Kousa O, Gujjula NR, Alla VM. Treatment of left ventricular Thrombus with direct oral anticoagulants: a retrospective observational study. Am J Med. 2020;133(12):1488–91.
doi: 10.1016/j.amjmed.2020.05.025
pubmed: 32598904
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2023.
Chen M, Liu D, Weidemann F, Lengenfelder BD, Ertl G, Hu K, Frantz S, Nordbeck P. Echocardiographic risk factors of left ventricular thrombus in patients with acute anterior myocardial infarction. ESC Heart Fail. 2021;8(6):5248–58.
doi: 10.1002/ehf2.13605
pubmed: 34498435
pmcid: 8712797
Duus LS, Pedersen S, Ravnkilde K, Galatius S, Fritz-Hansen T, Biering-Sørensen T, Olsen FJ. Association between the E-wave propagation index and left ventricular thrombus formation after ST-elevation myocardial infarction. Int J Cardiol. 2021;326:213–9.
doi: 10.1016/j.ijcard.2020.10.078
pubmed: 33152416
Sia CH, Leow AS, Tan BY, Low CJ, Kaur R, Yeo TC, Chan MY, Tay EL, Yeo LL, Yap ES, Loh JP. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention. Thromb Res. 2020;194:16–20.
doi: 10.1016/j.thromres.2020.06.003
pubmed: 32559523
Lee SH, Kim HK, Ahn JH, Kang MG, Kim KH, Bae JS, Cho SY, Koh JS, Park Y, Hwang SJ, Gorog DA, Tantry US, Bliden KP, Gurbel PA, Hwang JY, Jeong YH. Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. Eur Heart J. 2023;44:1718–28.
doi: 10.1093/eurheartj/ehad088
pubmed: 36857519
Watanabe R, Wada H, Sakakura M, Mori Y, Nakasaki T, Okugawa Y, Gabazza EC, Hayashi T, Nishioka J, Suzuki K, Shiku H, Nobori T. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. Am J Hematol. 2000;65(1):35–40.
doi: 10.1002/1096-8652(200009)65:1<35::AID-AJH6>3.0.CO;2-1
pubmed: 10936861
Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61–8.
doi: 10.1161/01.CIR.90.1.61
pubmed: 8026047
Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.
doi: 10.1056/NEJM199901143400207
pubmed: 9887164
Delemarre BJ, Visser CA, Bot H, Dunning AJ. Prediction of apical thrombus formation in acute myocardial infarction based on left ventricular spatial flow pattern. J Am Coll Cardiol. 1990;15(2):355–60.
doi: 10.1016/S0735-1097(10)80062-2
pubmed: 2299076
Johnson RC, Crissman RS, DiDio LJ. Endocardial alterations in myocardial infarction. Lab Invest. 1979;40(2):183–93.
pubmed: 431037
Colling ME, Tourdot BE, Kanthi Y. Inflammation, infection and venous thromboembolism. Circ Res. 2021;128(12):2017–36.
doi: 10.1161/CIRCRESAHA.121.318225
pubmed: 34110909
pmcid: 8202069
Levine GN, McEvoy JW, Fang JC, Ibeh C, McCarthy CP, Misra A, Shah ZI, Shenoy C, Spinler SA, Vallurupalli S, Lip GYH. Management of patients at risk for and with left ventricular Thrombus: a Scientific Statement from the American Heart Association. Circulation. 2022;146(15):e205–23.
doi: 10.1161/CIR.0000000000001092
pubmed: 36106537
Condello F, Maurina M, Chiarito M, Sturla M, Terzi R, Fazzari F, Sanz-Sanchez J, Cannata F, Condorelli G, Stefanini GG. Direct oral anticoagulants versus vitamin K antagonists in the treatment of left ventricular thrombosis: a systematic review and meta-analysis. Minerva Cardiol Angiol. 2022;70(6):666–76.
pubmed: 35080357